The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
NCT ID: NCT02537925
Last Updated: 2015-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
120 participants
INTERVENTIONAL
2014-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
NCT02739204
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
NCT04437329
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
NCT03427359
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
NCT04162873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are all recruited from the Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. All the patients provide written informed consent before enrollment. All eligible patients received a pretreatment evaluation including complete history and physical examination, endoscopic biopsy, routine laboratory tests for hematologic, renal and hepatic function as well as a dental and nutritional evaluation prior to treatment. Radiological investigations consisted of computed tomography (CT) scan or magnetic MRI of the nasopharynx, chest radiography, ultrasound of the upper abdomen and bone scintigraphy. Pathologic confirmation of nasopharyngeal cancer (NPC) was performed and re-classified according to the world health organization (WHO) subtypes.
2. Study design:
A total of 120 NPC patients are randomly and equally divided into two groups: Nedaplatin alone concurrent radiotherapy, Celecoxib plus nedaplatin concurrent radiotherapy. The tumor response will be evaluated by magnetic resonance imaging (MRI) after 4 weeks. The tumor responses including Complete Response (CR), Partial Response (PR) , Stable Disease (SD) and Progressive Disease (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. The show term or long term toxicity will be evaluated according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0. All the NPC patients are requested to be followed up with an expected average of every 3 months after the therapy.The other clinical outcomes including the first evidence of cancer progression or death from any cause, the occurrence of distant metastasis, and the relapse of a local or nodal tumor will be evaluated as well. The follow-up will be up to 2018.
3. Statistical Analysis:
Statistical Package for the Social Sciences (SPSS 13.0) is used to analyze the effect of celecoxib on the nedaplatin concurrent radiotherapy. Cox's regression model and Kaplan-Meier method is used to conduct survival analysis. Clinical outcomes including the tumor responses, 1-year/3-year/5-year overall survival (OS), progression free survival (PFS), distant metastasis failure-free survival (DMFS) and locoregional failure-free survival (LFFS) will be analyzed. The multivariate Cox's regression model is used to adjust the confounders, including age and body mass index. P value less than 0.05 will be considered to be statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
concurrent_radiochemotherapy
Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
Nedaplatin
40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
Concurrent Radiotherapy
The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
celecoxib_radiochemotherapy
Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
Celecoxib
Celecoxib 200mg bid po, to the end of concurrent radiotherapy
Nedaplatin
40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
Concurrent Radiotherapy
The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib
Celecoxib 200mg bid po, to the end of concurrent radiotherapy
Nedaplatin
40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
Concurrent Radiotherapy
The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
* With the Eastern Cooperative Oncology Group Performance Status (ECOG PS) as 0-1 score
* Serum hemoglobin ≥10gm/dL, platelet ≥100000/μL, neutrophil granulocyte absolute counting is 1500/μL
* Serum creatinine ≤1.25 times of upper normal limit (UNL), creatinine clearance rate ≥ 60 ml/min
* Serum bilirubin ≤ 1.5times of UNL, serum aspartate aminotransferase (AST) or glutamic-oxaloacetic transaminase(GOT)≤ 2.5 times of UNL, serum alanine aminotransferase (ALT) or glutamic-pyruvic transaminase (GPT) ≤ 2.5 times of UNL, alkaline phosphatase≤5 times of UNL
* The estimate overall survival (OS)\> 6 months
* With formal informed consent forms signed.
Exclusion Criteria
* With cognitive impairment or other malignancies
* With any contraindications for radiotherapy and chemotherapy (such as active phase of infection, myocardial infarction within 6 months, symptomatic heart disease, including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmias, in current immunosuppressive therapy)
* Current pregnancy, lactating women or women with fertility but don't take contraceptive measures yet
* With severe bone marrow dysfunction
* With bleeding tendency
* With abuse of drugs or alcohol addicts
* Who may have III-IV type of allergic reactions to any treatment in this study
* With termination of trial because of intolerable toxicity, other study drugs using during the clinical study, or unwilling to continue the treatment.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changjie Huang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Changjie Huang
head of the medical department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Changjie Huang
Role: PRINCIPAL_INVESTIGATOR
The third Affiliated Hospital of Guangxi Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The third Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, Tan KB, Low JS, Lai YF, Mow B, Hsu S, Loh KS, Tan L, Tan P, Goh BC. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol. 2006 Nov;17(11):1625-30. doi: 10.1093/annonc/mdl283. Epub 2006 Sep 28.
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin +/- low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial. J Cancer Res Ther. 2011 Oct-Dec;7(4):442-7. doi: 10.4103/0973-1482.92013.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NaningSPH_2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.